2. Academic Validation
  3. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment

  • Hematol Oncol Clin North Am. 2019 Aug;33(4):575-585. doi: 10.1016/j.hoc.2019.03.001.
Jennifer L Crombie 1,  Philippe Armand 2
Affiliations

Affiliations

  • 1 Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: [email protected].
  • 2 Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
PMID: 31229155 DOI: 10.1016/j.hoc.2019.03.001
Abstract

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is characterized by both clinical and molecular heterogeneity. Despite efforts to tailor therapy for individual patients, treatment remains uniform and a subset of patients have poor outcomes. The past decade has witnessed a dramatic expansion of our understanding of the genomic underpinnings of this disease, especially with the application of next-generation sequencing. In this review, the authors highlight the current genomic landscape of DLBCL and how this information provides a potential molecular framework for precision medicine-based strategies in this disease.

Keywords

Cell of origin; DLBCL; Diffuse large B-cell lymphoma; Genomic classifications; Precision medicine; Targeted therapy.

Figures